8-K: Ovid Therapeutics Secures $175.1M, Reports Positive OV329 Trial Results

Ovid Therapeutics announced a private placement expected to raise up to $175.1 million and positive Phase 1 topline results for its next-generation epilepsy drug candidate, OV329.

Summary

• Ovid Therapeutics Inc. entered into a Securities Purchase Agreement for a private placement (PIPE financing) to issue Series B convertible preferred stock and warrants.
• The PIPE financing is expected to generate gross proceeds of up to $175.1 million, including initial gross proceeds of approximately $80.8 million, before fees and expenses.
• Net proceeds from the initial closing will be used for research and development, general corporate expenses, and working capital needs.
• The company announced positive topline results from its Phase 1 healthy volunteer study for OV329, a next-generation GABA-aminotransferase inhibitor.
• OV329 demonstrated strong inhibitory activity and a potential best-in-category safety profile, with statistically significant inhibition of GABA-AT.
• Measures of inhibition for OV329 at a 5 mg dose (53% increase in inhibition) were comparable to or exceeded those published for therapeutic doses of vigabatrin (2-3g, ~35% inhibition).
• OV329 showed a favorable safety and tolerability profile, with all potentially treatment-related adverse events reported as mild and transient.
• No ophthalmic or retinal changes were observed during dosing and through Day 30 for OV329, differentiating it from vigabatrin which can accumulate in the retina.
• The Series B Preferred Stock is convertible into 1,000 shares of Common Stock per preferred share, subject to stockholder approval.
• Series A and Series B Warrants have an exercise price of $1.40 per share and are exercisable after stockholder approval, with varying termination dates.
• The company has agreed to register the Conversion Shares and Warrant Shares for resale, with a registration statement filing deadline of five business days after stockholder approval.

Sentiment

Score: 8

Explanation: The filing announces a substantial capital raise and highly positive clinical trial results for a key drug candidate, indicating strong progress and financial backing. The improved safety profile of OV329 compared to existing treatments is a significant positive.

Positives

• Successfully secured a significant capital raise of up to $175.1 million, bolstering financial resources for R&D and operations.
• Positive Phase 1 topline results for OV329 demonstrate strong GABAergic inhibitory activity, matching or exceeding that of therapeutic doses of vigabatrin.
• OV329 exhibited a favorable safety and tolerability profile in healthy volunteers, with all adverse events being mild and transient.
• Crucially, OV329 showed no evidence of ophthalmic or retinal changes, addressing a key safety concern associated with the first-generation GABA-AT inhibitor, vigabatrin.
• The company confirmed OV329 penetrates the brain, engages the target, and achieves biological modulation as expected, validating its mechanism of action.
• Advancement of OV329 into a Phase 2a study for drug-resistant focal onset seizures indicates pipeline progression.
• Multiple KCC2 direct activator programs (OV350, OV4071) are also advancing, providing a diversified pipeline with novel mechanisms of action.

Risks

• Uncertainties inherent in the preclinical and clinical development and regulatory approval processes.
• Impediments to the company's ability to achieve expected benefits of cost-savings efforts.
• Risks related to the company's ability to achieve its financial objectives.
• The risk that the company may not be able to realize the intended benefits of its business strategy.
• Risks related to the company's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions.
• Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions.
• The need for stockholder approval to increase the number of authorized shares of Common Stock and to approve the issuance of Conversion Shares and Warrant Shares, which could delay full conversion/exercise.

Future Outlook

The company plans to advance OV329 into a Phase 2a study for drug-resistant focal onset seizures in Q2 2026 and complete enabling studies for OV4071 for regulatory filings in Q1 2026, with a Phase 1/1b study to follow in Q2 2026. Multiple regulatory and clinical milestones are anticipated for the KCC2 direct activator programs (OV350, OV4071) in the next 12 months, targeting psychoses associated with Parkinson's disease, Lewy body dementia, and schizophrenia.

Management Comments

• "We believe these results reinforce OV329s therapeutic potential, and we are excited to advance it further in development alongside our rapidly progressing KCC2 direct activator portfolio, as we continue our commitment to developing innovative therapies for patients that address diseases and symptoms caused by excessive neural excitation." Dr. Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics.

Industry Context

The biopharmaceutical industry is actively seeking novel treatments for neurological and neuropsychiatric disorders, particularly drug-resistant epilepsies and psychoses, which represent significant unmet medical needs. Ovid Therapeutics' OV329, a next-generation GABA-AT inhibitor, aims to improve upon existing anti-seizure medicines like vigabatrin by offering a potentially superior safety profile, specifically avoiding ocular side effects. The company's KCC2 direct activator programs (OV350, OV4071) represent a differentiated approach to restoring neuronal excitation/inhibition balance, positioning Ovid at the forefront of developing innovative therapies for complex brain conditions.

Comparison to Industry Standards

• OV329's inhibition of GABA-AT, as measured by LICI 150ms on the APB muscle, showed a 53% increase in inhibition at a 5 mg dose, which matched or exceeded the approximately 35% inhibition reported for therapeutic doses of the first-generation GABA-AT inhibitor, vigabatrin (VGB, 2-3g), in prior studies.
• OV329 demonstrated a favorable safety and tolerability profile with no observed ophthalmic or retinal changes, a significant advantage over vigabatrin, which is known to preferentially partition and accumulate in the retina, leading to potential vision issues.

Corporate Governance

Related Party Transactions

• The company's Chief Executive Officer is among the investors participating in the PIPE financing.

Stakeholder Impact

• Shareholders: Potential for dilution from the conversion of Series B Preferred Stock and exercise of warrants, but also significant capital infusion and positive clinical data could drive long-term value. Stockholder approval is required for full conversion/exercise.
• Investors (PIPE): Acquire Series B Preferred Stock and warrants, offering potential upside from drug development success, with liquidation preferences and registration rights for resale.
• Patients: Positive Phase 1 results for OV329 and the advancement of KCC2 programs offer hope for new, potentially safer and more effective treatments for drug-resistant epilepsies and psychoses.
• Employees: The capital raise and pipeline progression provide increased stability and potential for growth within the company's R&D efforts.

Next Steps

• Initiate a Phase 2a randomized placebo-controlled study evaluating OV329 in adult patients with drug-resistant focal onset seizures in Q2 2026.
• Complete a final enabling study to support regulatory filings for OV4071 in early 2026.
• File for regulatory clearance for OV4071 in Q1 2026.
• Initiate a Phase 1/1b SAD/MAD study for OV4071 in Q2 2026.
• Conduct a ketamine challenge study for OV4071 in mid-2026 to establish proof-of-mechanism and de-risk future development in schizophrenia.
• Anticipate topline safety, tolerability, and PK data for OV350 (intravenous KCC2 direct activator) in Q4 2025.
• Obtain Requisite Stockholder Approval for the increase in authorized Common Stock and the issuance of Conversion Shares and Warrant Shares.
• File a registration statement with the SEC for the resale of Conversion Shares and Warrant Shares no later than the fifth business day following the Stockholder Approval.

Key Dates

Recommendation

The company has successfully secured a substantial capital infusion of up to $175.1 million, significantly strengthening its financial position. Concurrently, the positive topline Phase 1 results for OV329, demonstrating strong inhibitory activity and a superior safety profile compared to existing treatments like vigabatrin (specifically, no ophthalmic issues), represent a major de-risking event for a key pipeline asset. The clear path to Phase 2a for OV329 and the multiple upcoming milestones for the KCC2 direct activator programs (OV350, OV4071) indicate robust pipeline progression and multiple shots on goal. The inclusion of the CEO in the PIPE financing also signals strong internal confidence. These factors collectively suggest a strong positive outlook and significant potential for future value creation.

Keywords

Ovid Therapeutics, OVID, biopharmaceutical, epilepsy, GABA-AT inhibitor, OV329, KCC2 activator, OV350, OV4071, private placement, PIPE financing, Series B Preferred Stock, warrants, clinical trial, Phase 1, drug-resistant seizures, psychoses, Parkinson's disease, Lewy body dementia, schizophrenia, neuroscience, drug development, Nasdaq